ATE389651T1 - Als inhibitoren von c-met geeignete pyrrolzusammensetzungen - Google Patents
Als inhibitoren von c-met geeignete pyrrolzusammensetzungenInfo
- Publication number
- ATE389651T1 ATE389651T1 AT04781443T AT04781443T ATE389651T1 AT E389651 T1 ATE389651 T1 AT E389651T1 AT 04781443 T AT04781443 T AT 04781443T AT 04781443 T AT04781443 T AT 04781443T AT E389651 T1 ATE389651 T1 AT E389651T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- met
- compositions suitable
- compounds
- pyrrole compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49553503P | 2003-08-15 | 2003-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389651T1 true ATE389651T1 (de) | 2008-04-15 |
Family
ID=34193321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04781443T ATE389651T1 (de) | 2003-08-15 | 2004-08-16 | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20050101650A1 (de) |
| EP (1) | EP1660487B1 (de) |
| AT (1) | ATE389651T1 (de) |
| AU (1) | AU2004264440B2 (de) |
| CA (1) | CA2536470A1 (de) |
| DE (1) | DE602004012578T2 (de) |
| WO (1) | WO2005016920A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317453B1 (de) * | 2000-09-15 | 2006-08-09 | Vertex Pharmaceuticals Incorporated | Isoxazole und ihre verwendung als erk-inhibitoren |
| GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| EP2298748B1 (de) | 2004-11-18 | 2016-07-20 | Synta Pharmaceuticals Corp. | HSP90-Aktivität modulierende Triazolverbindungen |
| PL1889836T3 (pl) | 2005-08-24 | 2013-10-31 | Eisai R&D Man Co Ltd | Nowa pochodna pirydyny i pochodna pirymidyny (3) |
| US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
| CN101454311B (zh) | 2006-08-23 | 2013-03-27 | 卫材R&D管理有限公司 | 苯氧基吡啶衍生物的盐和其结晶及其制备方法 |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008153730A2 (en) * | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with mutations in c-met |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| CA2734172A1 (en) * | 2008-08-29 | 2010-03-04 | Genentech, Inc. | Diagnostics and treatments for vegf-independent tumors |
| CA2750565C (en) * | 2009-01-30 | 2015-10-20 | Glaxosmithkline Llc | Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| EP2560640A1 (de) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer |
| EP3450432A1 (de) | 2010-05-17 | 2019-03-06 | Incozen Therapeutics Pvt. Ltd. | Neuartige 3,5-disubstituierte-3h-imidazo[4,5-b]pyridin- und 3,5- disubstituierte-3h-[1,2,3]triazol[4,5-b]pyridin-verbindungen als modulatoren der proteinkinase |
| CN102146074B (zh) * | 2011-01-26 | 2013-02-06 | 江苏先声药物研究有限公司 | 吡咯衍生物的制备方法及应用 |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| EP2780010A1 (de) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Kombinationstherapie aus hsp90-inhibitoren mit braf-inhibitoren |
| AP3908A (en) | 2012-03-30 | 2016-11-24 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| MX2016012285A (es) | 2014-03-24 | 2017-01-23 | Genentech Inc | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. |
| US11795160B2 (en) | 2019-02-22 | 2023-10-24 | Insilico Medicine Ip Limited | Kinase inhibitors |
| WO2022179528A1 (en) | 2021-02-24 | 2022-09-01 | Insilico Medicine Ip Limited | Analogs for the treatment of disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056557A2 (en) * | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
| IL145757A (en) * | 2000-02-05 | 2007-12-03 | Vertex Pharma | History of pyrazole and pharmaceutical preparations containing them |
| EP1317453B1 (de) * | 2000-09-15 | 2006-08-09 | Vertex Pharmaceuticals Incorporated | Isoxazole und ihre verwendung als erk-inhibitoren |
| CA2445568A1 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| JP4357295B2 (ja) * | 2001-08-03 | 2009-11-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール誘導キナーゼインヒビターとその使用 |
-
2004
- 2004-08-16 WO PCT/US2004/026749 patent/WO2005016920A1/en not_active Ceased
- 2004-08-16 EP EP04781443A patent/EP1660487B1/de not_active Expired - Lifetime
- 2004-08-16 CA CA002536470A patent/CA2536470A1/en not_active Abandoned
- 2004-08-16 AU AU2004264440A patent/AU2004264440B2/en not_active Ceased
- 2004-08-16 AT AT04781443T patent/ATE389651T1/de not_active IP Right Cessation
- 2004-08-16 US US10/919,774 patent/US20050101650A1/en not_active Abandoned
- 2004-08-16 DE DE602004012578T patent/DE602004012578T2/de not_active Expired - Lifetime
-
2006
- 2006-03-22 US US11/387,126 patent/US7314885B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004264440A1 (en) | 2005-02-24 |
| WO2005016920A1 (en) | 2005-02-24 |
| US20060173055A1 (en) | 2006-08-03 |
| US7314885B2 (en) | 2008-01-01 |
| DE602004012578D1 (de) | 2008-04-30 |
| AU2004264440B2 (en) | 2008-10-23 |
| EP1660487A1 (de) | 2006-05-31 |
| CA2536470A1 (en) | 2005-02-24 |
| DE602004012578T2 (de) | 2008-12-11 |
| EP1660487B1 (de) | 2008-03-19 |
| US20050101650A1 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| ATE420883T1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| UA84930C2 (ru) | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения | |
| DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
| ATE493401T1 (de) | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen | |
| WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
| DE602006021776D1 (de) | Als kinaseinhibitoren geeignete aminopyrimidine | |
| TW200633980A (en) | Pyridones useful as inhibitors of kinases | |
| ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
| ATE497961T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
| ATE528309T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |